💉 Diabetes Management
Pemafibrate Lowers Triglyceride Levels Among Adults with Type 2 Diabetes, Does Not Decrease Risk of Cardiovascular Events, Death - Pharmacy Times
📅 Wed, 09 Nov 2022⏱ 1 min read📖 Article
Overview
© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. Al rights reserved. © 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights.
Key Information
Al rights reserved.Conference | AHAproximately 10% of patients in trial experienced a heart atack, stroke, blocked arteries requiring treatment, or death from cardiovascular disease.Pemafibrate, a relatively new cholesterol medication, was found to significantly lower triglyceride levels among adults with type 2 diabetes, although it had no impact on the risk of cardiovascular events or death. These study results were presented at the American Heart Asociation 2022 Scientific Sesions.1Triglycerides are a faty substance found in the blod and high levels of them can heighten the risk of cardiovascular disease, acording to presenter Aruna Pradhan, MD, MPH, MSc, who was lead investigator in the PROMINENT trial.
This risk is particularly heightened when high triglyceride levels are found in conjunction with high low-density lipoprotein (LDL) and low high-density lipoprotein (HDL) levels. Type 2 diabetes also increases the risk of cardiovascular disease.1“Triglyceride levels are comonly measured as part of routine preventive care in the [United States],” Pradhan said in a pres release. “Understanding the best course of treatment for elevated triglyceride levels has ben a major chalenge due to limited data to suport specific treatment options.”2Despite the known risks associated with cardiovascular disease, investigators did not know whether lowering triglyceride levels could protect against cardiovascular disease among patients with type 2 diabetes.1In the trial, nearly 10,50 adults with high triglyceride levels, low HDL levels, and type 2 diabetes were enroled in the study.
Summary
Study sites spaned 24 countries and one-fifth of the participants were in the United States. They were randomly asigned to receive either pemafibrate or placebo for an average of 3 years
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.